[1]Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1):9-29.
[2]Anuradha S,Webb PM, Blomfield P, et al. Survival of Australian women with invasive epithelial ovarian cancer: a population-based study[J]. Med J Aust, 2014, 201(5): 283-288.
[3]Garcia-Jove Navarro M, Basset C, Arconde’guy T, et al. Api5 contributes to E2F1 control of the G1/S cell cycle phase transition[J]. PLoeS One, 2013, 8(8):e71443.
[4]Gong YQ, Han FJ, Wu XK, et al. Progress in study on etiology of ovarian epithelial cancer[J].Frontiers of Medicine, 2010,39(5):18-20. (in Chinese)
宫艳秋,韩凤娟,吴效科,等. 卵巢上皮性癌病因学研究进展[J]. 医学前沿,2010,39(5):18-20.
[5]Walters Haygood, CL, Arend RC, Straughn JM, et al. Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival[J]? World J Stem Cells, 2014, 6(4):441-447.
[6]Ma RQ, Ye X, Cheng HY,et al. Expressions and clinical significance of ROBO4 in both serum and tumor tissues in patients with epithelial ovarian cancer[J]. Acta Anatomica Sinica, 2014, 45(1):64-69. (in Chinese)
马瑞琼,叶雪,程洪艳,等. ROBO4在上皮性卵巢癌组织和血清中的表达及临床意义[J]. 解剖学报,2014,45(1):64-69.
[7]Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation[J]. Development, 2013, 140(15):3079-3093.
[8]Stone A, Sutherland RL, Musgrove EA. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics[J]. Crit Rev Oncog, 2012,17(2):175-198.
[9]Zhao HL, Zhao XX, Wang YQ. The progress of API5[J]. Anhui Agricultural Science Bulleti, 2011,17(7):46. (in Chinese)
赵慧玲,赵鑫鑫,汪艳秋. API5相关的研究进展[J]. 安徽农学通,2011,17(7):46.
[10]Morris EJ, Michaud WA, Ji JY, et al. Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo[J]. PLoS Genet, 2006, 2(11):e196.
[11]Noh KH, Kim SH, Kim JH, et al. API5 confers tumoral immune escape through FGF2-dependent cell survival pathway[J]. Cancer Res, 2014, 74(13):3556-3566.
[12]Tewari M1, Yu M, Ross B, et al. AAC-11, a novel cDNA that inhibits apoptosis after growth factor withdrawal[J]. Cancer Res, 1997, 57(18):4063-4069.
[13]Kim JW, Cho HS, Kim JH, et al. AAC-11 overexpression induces invasion and protects cervical cancer cells from apoptosis[J]. Lab Invest, 2000, 80(4):587-594.
[14]Cho H, Chung JY, Song KH, et al. Apoptosis inhibitor-5 overexpression is associated with tumor progression and poor prognosis in patients with cervical cancer[J]. BMC Cancer, 2014, 14(1):545.
[15]Clegg N, Ferguson C, True LD, et al. Molecular characterization of prostatic small-cell neuroendocrine carcinoma[J]. Prostate, 2003, 55(1):55-64.
[16]Sasaki H, Moriyama S, Yukiue H, et al. Expression of the antiapoptosis gene, AAC-11, as a prognosis marker in nonsmall cell lung cancer[J]. Lung Cancer, 2001, 34(1):53-57.
[17]Wang Z, Liu H, Liu B, et al. Gene expression levels of CSNK1A1 and AAC-11, but not NME1, in tumor tissues as prognostic factors in NSCLC patients[J]. Med Sci Monit, 2010, 16(8):357-364.
[18]Li D, Liu Y, Li H, et al. MicroRNA-1 promotes apoptosis of hepatocarcinoma cells by targeting apoptosis inhibitor-5 (API-5)[J]. FEBS Lett, 2015, 589(1):68-76.
[19]Upraity S, Kazi S, Padul V, et al. MiR-224 expression increases radiation sensitivity of glioblastoma cells[J]. Biochem Biophys Res Commun, 2014, 448(2):225-230.
[20]Ren K, Zhang W, Shi Y, et al. Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway[J]. Pathol Oncol Res, 2010,16(2):229-237.
|